Atomoxetine Sandoz 60 mg 노르웨이 - 노르웨이어 - Statens legemiddelverk

atomoxetine sandoz 60 mg

sandoz - københavn - atomoksetinhydroklorid - kapsel, hard - 60 mg

Atomoxetine Sandoz 80 mg 노르웨이 - 노르웨이어 - Statens legemiddelverk

atomoxetine sandoz 80 mg

sandoz - københavn - atomoksetinhydroklorid - kapsel, hard - 80 mg

Livicort 64 mikrog/ dose 노르웨이 - 노르웨이어 - Statens legemiddelverk

livicort 64 mikrog/ dose

mcneil sweden ab - budesonid - nesespray, suspensjon - 64 mikrog/ dose

Givlaari 유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

givlaari

alnylam netherlands b.v. - givosiran - porfyrier, nedsatt - ulike alimentary tract and metabolism products - behandling av akutt hepatisk porfyri (ahp) i voksne og ungdom i alderen 12 år og eldre.

Staquis 유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

staquis

pfizer europe ma eeig  - crisaborole - dermatitt, atopisk - andre dermatologiske preparater - staquis er indisert for behandling av mild til moderat atopisk eksem hos voksne og paediatric pasienter fra 2 års alder med ≤ 40% body surface area (bsa) påvirkes.

Filsuvez 유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

filsuvez

amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - preparater for behandling av sår og sår - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.

Oxbryta 유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

oxbryta

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Tabrecta 유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karsinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Hemgenix 유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

hemgenix

csl behring gmbh - etranacogene dezaparvovec - hemofili b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Litfulo 유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

litfulo

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunsuppressive - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.